India Pharma Outlook Team | Tuesday, 07 June 2022
Pfizer Inc said on Monday it would spend $120 million to boost
manufacturing of its COVID-19 antiviral treatment at its Michigan plant, as demand ramps up.
Use of the pill, Paxlovid, authorized to treat newly infected, at-risk people to prevent severe illness, has soared recently as infections rise. Biden administration officials have pushed for the wider use of Paxlovid, which the government distributes for free.
